| Literature DB >> 29769439 |
Michal Beffinger1, Paulino Tallón de Lara1, Sònia Tugues1, Marijne Vermeer1, Yannick Montagnolo1, Isabel Ohs1, Virginia Cecconi1, Giulia Lucchiari1, Aron Gagliardi1, Nikola Misljencevic1, James Sutton2, Roman Spörri3, Burkhard Becher1, Anurag Gupta1, Maries van den Broek1.
Abstract
Myeloid leukocytes are essentially involved in both tumor progression and control. We show that neo-adjuvant treatment of mice with an inhibitor of CSF1 receptor (CSF1R), a drug that is used to deplete tumor-associated macrophages, unexpectedly promoted metastasis. CSF1R blockade indirectly diminished the number of NK cells due to a paucity of myeloid cells that provide the survival factor IL-15 to NK cells. Reduction of the number of NK cells resulted in increased seeding of metastatic tumor cells to the lungs but did not impact on progression of established metastases. Supplementation of mice treated with CSF1R-inhibitor with IL-15 restored numbers of NK cells and diminished metastasis. Our data suggest that CSF1R blockade should be combined with administration of IL-15 to reduce the risk of metastasis.Entities:
Keywords: Cancer; Immunology; NK cells; Oncology
Mesh:
Substances:
Year: 2018 PMID: 29769439 PMCID: PMC6012573 DOI: 10.1172/jci.insight.97792
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708